GlassScriptPhysician profile
Tamra Morrow
NPI 1699006015
$5,217.03
in general payments reported to CMS, 2019-2025
34 companies · $949 in 2025
The $949 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,425 · 2022: $1,080 · 2023: $907 · 2024: $855 · 2025: $949.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,711.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,711.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $765.28 | 2021-2025 | |
| Glaxosmithkline, LLC. | $560.70 | 2021-2023 | Trelegy Ellipta, Shingrix |
| Otsuka America Pharmaceutical, INC. | $531.18 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Lilly USA, LLC | $514.46 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $292.21 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $272.04 | 2021-2023 | Repatha, Otezla |
| Novo Nordisk INC | $269.56 | 2021-2025 | Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $208.35 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $194.32 | 2021-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $186.88 | 2022-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $158.25 | 2021-2022 | |
| Axsome Therapeutics, INC. | $139.78 | 2022-2025 | Auvelity, Symbravo |
| Astellas Pharma US INC | $139.38 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $116.45 | 2021-2023 | Verquvo, Steglatro, Belsomra |
| Corium, LLC | $116.32 | 2023-2024 | Azstarys |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $106.53 | 2021-2024 | Uzedy, Austedo |
| Supernus Pharmaceuticals, INC. | $106.53 | 2025 | Qelbree |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.91 | 2021-2022 | |
| Vertex Pharmaceuticals Incorporated | $53.73 | 2025 | |
| Janssen Pharmaceuticals, INC | $49.21 | 2021-2024 | Spravato |
| Biohaven Pharmaceuticals, INC. | $48.86 | 2021 | |
| Lundbeck LLC | $46.30 | 2024 | Abilify Asimtufii, Rexulti |
| Idorsia Pharmaceuticals US INC | $46.03 | 2023-2024 | Quviviq |
| Amarin Pharma, INC. | $39.69 | 2021 | |
| Organon LLC | $34.36 | 2021-2022 | |
| Pfizer INC. | $20.16 | 2023 | |
| Harmony Biosciences LLC | $20.04 | 2024 | |
| Sanofi Pasteur INC. | $15.69 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $14.52 | 2024 | |
| Novartis Pharmaceuticals Corporation | $13.72 | 2022 | |
| Biogen, INC. | $13.51 | 2021 | |
| Therapeuticsmd, INC. | $13.39 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.18 | 2022 | |
| Mylan Specialty L.P. | $11.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamra Morrow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.